Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday.

Abivax SA’s shares pared gains after France’s finance ministry said it has not been contacted by Eli Lilly & Co. about a ...

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech ...

Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with ...

Abivax (ABVX) stays a Buy as obefazimod UC data fuels multi‑billion potential; 2026 Phase 3/NDA catalysts loom and M&A ...

French newspaper La Lettre said the Paris-based biotech – which is listed on the Nasdaq – has been on Lilly's radar after ...

Abivax shares have risen steadily since late July, when the company traded at 42.6 euros. The company announced positive Phase 3 trial results for a drug to treat inflammatory bowel disease on July 23 ...

Investing.com -- Eli Lilly is preparing to offer €15 billion to acquire French biotech company Abivax, according to a Monday report from La Lettre. The U.S. pharmaceutical giant has not yet submitted ...

We recently published 10 Market Stars Behind Millionaire-Making in 2025. ABIVAX Societe Anonyme (NASDAQ:ABVX) is last year’s ...

France's Finance Ministry refutes reports of Eli Lilly's intent to acquire French biotech Abivax for €15 billion. Abivax shares spiked following the rumors but receded after the Ministry's denial.

Shares in Nasdaq-listed Abivax soared in pre-market trading on Monday after reports emerged that pharma giant Eli Lilly was ...